Cargando…
Correlation of Perfusion MRI and (18)F-FDG PET Imaging Biomarkers for Monitoring Regorafenib Therapy in Experimental Colon Carcinomas with Immunohistochemical Validation
OBJECTIVES: To investigate a multimodal, multiparametric perfusion MRI / (18)F-fluoro-deoxyglucose-((18)F-FDG)-PET imaging protocol for monitoring regorafenib therapy effects on experimental colorectal adenocarcinomas in rats with immunohistochemical validation. MATERIALS AND METHODS: Human colorect...
Autores principales: | Eschbach, Ralf S., Fendler, Wolfgang P., Kazmierczak, Philipp M., Hacker, Marcus, Rominger, Axel, Carlsen, Janette, Hirner-Eppeneder, Heidrun, Schuster, Jessica, Moser, Matthias, Havla, Lukas, Schneider, Moritz J., Ingrisch, Michael, Spaeth, Lukas, Reiser, Maximilian F., Nikolaou, Konstantin, Cyran, Clemens C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4323201/ https://www.ncbi.nlm.nih.gov/pubmed/25668193 http://dx.doi.org/10.1371/journal.pone.0115543 |
Ejemplares similares
-
Regorafenib Effects on Human Colon Carcinoma Xenografts Monitored by Dynamic Contrast-Enhanced Computed Tomography with Immunohistochemical Validation
por: Cyran, Clemens C., et al.
Publicado: (2013) -
Monitoring Cell Death in Regorafenib-Treated Experimental Colon Carcinomas Using Annexin-Based Optical Fluorescence Imaging Validated by Perfusion MRI
por: Kazmierczak, Philipp M., et al.
Publicado: (2015) -
Contrast-Enhanced Ultrasound with VEGFR2-Targeted Microbubbles for Monitoring Regorafenib Therapy Effects in Experimental Colorectal Adenocarcinomas in Rats with DCE-MRI and Immunohistochemical Validation
por: Eschbach, Ralf Stefan, et al.
Publicado: (2017) -
(68)Ga-TRAP-(RGD)(3) Hybrid Imaging for the In Vivo Monitoring of α(v)ß(3)-Integrin Expression as Biomarker of Anti-Angiogenic Therapy Effects in Experimental Breast Cancer
por: Kazmierczak, Philipp M., et al.
Publicado: (2016) -
(18)F–FDG-PET/CT and diffusion-weighted MRI for monitoring a BRAF and CDK 4/6 inhibitor combination therapy in a murine model of human melanoma
por: Eschbach, Ralf S., et al.
Publicado: (2018)